Rep. Jefferson Shreve Sells Off Shares of DexCom, Inc. (NASDAQ:DXCM)

Representative Jefferson Shreve (R-Indiana) recently sold shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on May 08th, the Representative disclosed that they had sold between $15,001 and $50,000 in DexCom stock on April 7th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 – $100,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 4/17/2025.
• Purchased $50,001 – $100,000 in shares of Applied Materials (NASDAQ:AMAT) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Caterpillar (NYSE:CAT) on 4/17/2025.
• Sold $15,001 – $50,000 in shares of Lululemon Athletica (NASDAQ:LULU) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Western Digital (NASDAQ:WDC) on 4/17/2025.
• Sold $15,001 – $50,000 in shares of Zoetis (NYSE:ZTS) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Stryker (NYSE:SYK) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of CSX (NASDAQ:CSX) on 4/17/2025.
• Purchased $15,001 – $50,000 in shares of Ross Stores (NASDAQ:ROST) on 4/17/2025.

DexCom Trading Up 0.2%

DXCM stock traded up $0.16 during trading on Monday, hitting $84.83. 1,945,157 shares of the company traded hands, compared to its average volume of 4,322,656. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a market capitalization of $33.26 billion, a PE ratio of 59.23, a P/E/G ratio of 2.30 and a beta of 1.43. The company has a 50-day moving average of $71.08 and a 200-day moving average of $77.22. DexCom, Inc. has a 1 year low of $57.52 and a 1 year high of $132.26.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. During the same period last year, the business posted $0.32 earnings per share. Analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DexCom

Several hedge funds have recently bought and sold shares of DXCM. Watts Gwilliam & Co. LLC bought a new stake in shares of DexCom in the 4th quarter valued at about $3,334,000. Congress Asset Management Co. raised its stake in shares of DexCom by 5,456.9% during the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after buying an additional 1,332,522 shares during the period. Janney Montgomery Scott LLC raised its holdings in shares of DexCom by 2,226.6% during the fourth quarter. Janney Montgomery Scott LLC now owns 232,543 shares of the medical device company’s stock valued at $18,085,000 after acquiring an additional 222,548 shares during the last quarter. First Hawaiian Bank grew its holdings in shares of DexCom by 556.1% during the fourth quarter. First Hawaiian Bank now owns 23,159 shares of the medical device company’s stock worth $1,801,000 after buying an additional 19,629 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in shares of DexCom in the 4th quarter worth $5,812,000. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on DXCM shares. Robert W. Baird reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. Barclays lifted their price objective on DexCom from $90.00 to $93.00 and gave the company an “equal weight” rating in a research note on Monday, May 5th. Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley lifted their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Finally, Piper Sandler lowered their price target on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a report on Friday, May 2nd. Five analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $98.11.

Insider Activity

In related news, EVP Jereme M. Sylvain sold 7,000 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total value of $516,810.00. Following the transaction, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at $10,002,636.06. This trade represents a 4.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares in the company, valued at approximately $22,063,918.86. This trade represents a 4.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last quarter. Insiders own 0.32% of the company’s stock.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana’s 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana’s 6th Congressional District. He declared candidacy for the 2026 election.

Email [email protected] to notify us of updates to this biography.
Jefferson Shreve earned a bachelor’s degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve’s career experience includes working as a real estate executive.

Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.